Abstract
S100A10, which is also known as p11, is located in the plasma membrane and forms a heterotetramer with annexin A2. The heterotetramer, comprising of two subunits of annexin A2 and S100A10, activates the plasminogen activation pathway, which is involved in cellular repair of normal tissues. Increased expression of annexin A2 and S100A10 in cancer cells leads to increased levels of plasmin—which promotes the degradation of the extracellular matrix—increased angiogenesis, and the invasion of the surrounding organs. Although many studies have investigated the functional role of annexin A2 in cancer cells, including ovarian cancer, S100A10 has been less studied. We recently demonstrated that high stromal annexin A2 and high cytoplasmic S100A10 expression is associated with a 3.4-fold increased risk of progression and 7.9-fold risk of death in ovarian cancer patients. Other studies have linked S100A10 with multidrug resistance in ovarian cancer; however, no functional studies to date have been performed in ovarian cancer cells. This article reviews the current understanding of S100A10 function in cancer with a particular focus on ovarian cancer.
Highlights
Ovarian cancer is the most lethal gynecological malignancy with a 5-year survival rate of only about 46% [1]
Together these findings suggest that S100A10 plays an important role progression of serous ovarian cancer and chemotherapy resistance
S100A10 expression is increased increased in tumor tissue at relapse with chemotherapy-resistant disease compared to tumor tissue at in tumor tissue at relapse with chemotherapy-resistant disease compared to tumor tissue at diagnosis
Summary
Ovarian cancer is the most lethal gynecological malignancy with a 5-year survival rate of only about 46% [1]. Other identified causes for chemotherapy resistance include upregulation of ATP-binding cassette (ABC) transporters responsible for efflux of cancer therapies [7], activation of cancer stem cells, and epithelial to mesenchymal transition (EMT), as well as alterations to the tumor microenvironment [8,9]. Predicting the response to drug therapies remains a major challenge in ovarian cancer. Recent empirically studies havefrom usedthe a the prediction of the response second-line chemotherapy is determined chemoresponse assay (CRA). Recent studies have linked S100A10 with chemotherapy resistance and poor prognosis in serous ovarian cancer have been performed to date.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
